Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1CZA8 | ISIN: IL0011063760 | Ticker-Symbol:
NASDAQ
01.11.24
18:18 Uhr
1,730 US-Dollar
+0,020
+1,17 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INTERCURE LTD Chart 1 Jahr
5-Tage-Chart
INTERCURE LTD 5-Tage-Chart

Aktuelle News zur INTERCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoIntercure Ltd. - 6-K, Report of foreign issuer1
13.09.Intercure Ltd. - 6-K, Report of foreign issuer1
30.08.InterCure reports 1H results1
30.08.InterCure Ltd.: InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million732Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues).Both quarters (Q1 and Q2 of 2024) ended with positive...
► Artikel lesen
28.08.InterCure partners with Cookies to launch cannabis pharmacies in Germany1
28.08.InterCure expands strategic partnership with Cookies to Germany1
28.08.InterCure Announces Expansion of its Strategic partnership with Cookies to Germany210InterCure expands its European footprint to launch Cookies Corners licensed pharmacies in Germany alongside differentiated online platforms with the official cookies retail experience, enhancing...
► Artikel lesen
28.08.Intercure Ltd. - 6-K, Report of foreign issuer2
21.05.Intercure Ltd. - 6-K, Report of foreign issuer1
01.05.InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million229NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts...
► Artikel lesen
01.04.InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million384NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2023. All amounts...
► Artikel lesen
22.03.InterCure Ltd.: InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint455InterCure provides an update following recent Cannabis Reform in Germany Expects to launch its first products in Germany in the coming months The Company continues to closely watch...
► Artikel lesen
31.01.InterCure Ltd.: InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain259NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1